WO1998024807A2 - Antagonistes de la somatostatine - Google Patents

Antagonistes de la somatostatine Download PDF

Info

Publication number
WO1998024807A2
WO1998024807A2 PCT/US1997/022251 US9722251W WO9824807A2 WO 1998024807 A2 WO1998024807 A2 WO 1998024807A2 US 9722251 W US9722251 W US 9722251W WO 9824807 A2 WO9824807 A2 WO 9824807A2
Authority
WO
WIPO (PCT)
Prior art keywords
cys
trp
lys
phe
nal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/022251
Other languages
English (en)
Other versions
WO1998024807A3 (fr
Inventor
Barry Morgan
William Murphy
David H. Coy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Tulane University
Ipsen Bioscience Inc
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Tulane University
Ipsen Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/855,204 external-priority patent/US6262229B1/en
Priority to AU76248/98A priority Critical patent/AU728224B2/en
Priority to MXPA99004944A priority patent/MXPA99004944A/es
Priority to DE69736193T priority patent/DE69736193T2/de
Priority to KR10-1999-7004835A priority patent/KR100479149B1/ko
Priority to BR9714376A priority patent/BR9714376A/pt
Priority to NZ335879A priority patent/NZ335879A/xx
Priority to CA002274144A priority patent/CA2274144C/fr
Priority to IL13016697A priority patent/IL130166A0/xx
Priority to JP52580198A priority patent/JP4124820B2/ja
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS, Tulane University, Ipsen Bioscience Inc filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to EP97949758A priority patent/EP0956296B1/fr
Priority to PL97334089A priority patent/PL334089A1/xx
Publication of WO1998024807A2 publication Critical patent/WO1998024807A2/fr
Publication of WO1998024807A3 publication Critical patent/WO1998024807A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • somatostatin is comprised of both a 14-amino acid isoform (somatostatin-14) and a 28-amino acid isoform
  • SSTR-2 somatostatin type-5 receptor
  • SSTR-5 somatostatin type-5 receptor
  • a 1 is a D- or L-isomer of an aromatic amino acid, or is deleted;
  • a 2 - is a D-isomer selected from the group consisting of Cys, Pen, an aromatic amino acid, or an aliphatic amino acid;
  • a 3 is an aromatic amino acid
  • a 4 is Trp or D-Trp
  • a 6 is Thr, Thr(Bzl), Gly, Ser, an Eaa, or an aliphatic amino acid
  • a 7 is Cys, Pen, or an aromatjkic or an aliphatic amino acid
  • a 8 is a D- or L-isomer selected from the group consisting of Thr, Ser, an aromatic amino acid, or an aliphatic amino acid
  • each of R 1 , and R 2 is, independently, H or substituted (e.g., one to four times) or unsubstituted lower alkyl, aryl , aryl lower alkyl, heterocycle, heterocycle lower alkyl, E 1 S0 2 or E ⁇ CO (where E x is aryl, aryl lower alkyl, heterocycle, or heterocycle lower alkyl) , where said substituent is halo, lower alkyl, hydroxy, halo lower alkyl , or hydroxy lower alkyl ; and R 3 is OH, NH 2 , C ⁇ alkoxy, or NH-Y-CH 2 -Z, wherein Y is a C 1 ⁇ 12 hydrocarbon moiety and Z is H,
  • a 2 is D-Cys
  • a 7 is Cys
  • a 4 is D-Trp.
  • a 1 is an L-aromatic amino acid.
  • a 1 and A 3 independently, is 3-_Nal, o-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2 , CN, or N0 2 ) , p-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2 , CN, or N0 2 ), m-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2 , CN, or N0 2 ) , F 5 ,-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(l), Bta, Bip, Npa, or Pal;
  • a 6 is Thr, Ser, Tie, Thr(Bzl), Abu, Ala, lie, Leu, Gly, Nle, /3-Al , Gaba, or Val; and A 8
  • a 1 is 3-Nal, Npa, Igl, Phe, p-F-Phe, Trp, p-Cl-Phe, or p-CN- Phe;
  • a 3 is Tyr, Tyr(I), or Pal;
  • a 6 is Val, Tie, Nle, lie, or Leu;
  • a 8 is p-F-Phe, /3-Nal, Tyr, Dip, pCl-Phe, Igl, or p-CN- Phe;
  • R x is H, CH 3 CO, 4- (2 -hydroxyethyl) -lpiperazinylacetyl , or 4- (2-hydroxyethyl) -lpiperizineethanesulfonyl ;
  • R 2 is H; and
  • R 3 is NH 2 .
  • a 1 is a D-aromatic amino acid.
  • a 1 is D-/3-Nal, D-o-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2 , CN, or N0 2 ) , D-p-X-Phe (where X is H, OH, CH 3 , halo, 0CH 3 , NH 2 , CN, or N0 2 ) , D-m-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2 , CN, or N0 2 ) , F 5 -Phe, D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D- His, D-Igl, D-Tyr(I), D-Bta, D-Bip, D-Npa, or D-Pal; A 3
  • a 1 is D-/3-Nal, D-
  • Npa D-Igl, D-Phe, D-p-F-Phe, D-Trp, D-p-Cl-Phe, or D-p-CN-
  • a 3 is Tyr, Tyr(I), or Pal;
  • a 6 is Val, Tie, Nle, lie, or Leu;
  • a 8 is p-F-Phe, /3-Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN- Phe;
  • R 1 is-H, CH 3 CO, 4- (2 -hydroxyethyl) -1-piperazinylacetyl , or 4- (2 -hydroxyethyl) -lpiperizineethanesulfonyl ;
  • R 2 is H; and
  • R 3 is NH 2 .
  • a 1 is deleted, R 1 is substituted or unsubstituted E-.CO, and R 2 is H.
  • R is substituted or unsubstituted EjCO (where E x is phenyl, /3-naphthylmethyl, ⁇ - pyridinylmethyl , or 3-indolylmethyl) ;
  • a 3 is /3-Nal, o-X-Phe
  • Trp Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal;
  • a 6 is Thr, Ser, Tie, Thr(Bzl), Abu, Ala, lie, Leu,
  • a 8 is the D- or L-isomer of Thr, Dip, F 5 -Phe, p-X-Phe (where X is H, OH, CH 3 ,, halo,
  • OCH 3 OCH 3 , NH 2 , CN, or N0 2 ) , Igl, Tyr(Bzl), or /3-Nal.
  • R 1 is E j CO (where E- L is 4-hydroxy-phenyl, /3-naphthylmethyl, or phenyl); A 3 is
  • a 6 is Val, Tie, Nle, lie, or Leu;
  • a 8 is p-F-Phe, /3-Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-Phe; R 3 is
  • R 3 together with the carbonyl group of A 8 attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl.
  • a 1 is the D- or L-isomer of ⁇ - Nal, o-X-Phe (where X is H, OH, CH3 , halo, 0CH3 , NH2 , CN, or N02) , p-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2 , CN, or N0 2 ) , m-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2 , CN, or N0 2 ) , F 5 -Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A 3
  • a 1 is the D- or Lisomer of /3-Nal, Phe, p-F-Phe, Trp, p-Cl-Phe, or p- CN-Phe;
  • a 3 is Tyr, Tyr(I), or Pal;
  • a 6 is Val, Tie, Nle, lie, or Leu;
  • a 3 is p-F-Phe, /3-Nal, Tyr, Dip, p-Cl-Phe, Igl, or p- CN-Phe;
  • R x is H, CH 3 CO, 4- (2 -hydroxyethyl) -1- pipera z inyl ace ty1 , or 4 - ( 2 - hydroxye t hy1 ) - 1 - piperizineethanesulfonyl ;
  • R 2 is H, and R 3 , together with the carboxy group of A 8 attached thereto, are reduced to form H or CH 3 0H.
  • a 2 is a D-aromatic amino acid or a D-aliphatic amino acid
  • a 7 is an aromatic amino acid or an aliphatic amino acid
  • a 4 is D-Trp.
  • a 1 is an L- amino acid and A 2 is a D-aromatic amino acid.
  • a 1 , A 3 , and A 7 independently, is 3-Nal, o-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2 , CN, or N0 2 ) , p-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2 , CN, or N0 2 ) , m-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2 , CN, or N0 2 ) , F 5 -Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal;
  • a 2 is D- /3-Nal, D-o-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2
  • a 1 is /3-Nal or
  • a 2 is D-Cpa or D-Phe;
  • a 3 is Phe or Tyr;
  • a 6 is Abu, Thr, or Val;
  • a 7 is Phe; and
  • a 8 is Thr;
  • R ⁇ is H, CH 3 CO, 4- (2- hydroxyethyl) -1-piperazinylacetyl , or 4- (2 -hydroxyethyl) -1- piperizineethanesulfonyl ;
  • a 1 is a D-amino acid and A 2 is a D-aromatic amino acid.
  • a 1 and A 2 independently, is D- -Nal, D-o-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2 , CN, or N0 2 ) , D-p-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 ,, NH 2 , CN, or N0 2 ) , D-m-X-Phe (where X is H, OH, CH 3 , halo, OCH 3 , NH 2 , CN, or N0 2 ) , D-F 5 -Phe, D-Trp, D- Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-Bta
  • a 1 is D-/3-Nal or D-Phe;
  • a 2 is D-Cpa or D-Phe;
  • a 3 is Phe or Tyr;
  • a 6 is Thr or Val;
  • a 7 is Phe; and
  • a 8 is Thr;
  • R x is H, CH 3 CO, 4- (2- hydroxyethyl ) -1-piperazinylacetyl, or 4- (2 -hydroxyethyl) -1- piperizineethanesulfonyl ;
  • R 2 is H; and
  • R 3 is NH 2 .
  • Examples of compounds of the present invention include the following:
  • H 2 -Phe-D-Cys-Pal-D-Trp-Lys-Val -Cys- /3-Nal -NH 2 (Analog No. 4) ; (H) (CH 3 CO)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-/3-Nal-NH 2 ; (H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D- Cys -Pal -D-Trp-Lys-Val -Cys -/3-Nal -NH 2 ;
  • H 2 -Dip-D-Cys-Pal -D-Trp-Lys-Val -Cys-/3-Nal -NH 2 (Analog No . 13) ;
  • H 2 -m- F- Phe -D-Cys -Pal -D-Trp-Lys -Val -Cys -m-F- Phe -NH 2 (Analog No. 14) ;
  • H 2 -Bip-D-Cys-Tyr-D-Trp-Lys-lie-Cys-Bip-NH 2 (Analog No. 36)
  • H 2 -p-F-Phe-D-Cys-His -D-Trp-Lys-Val -Cys-p-F-Phe-NH 2 (Analog No. 38)
  • H 2 -/3-Nal -D-Cpa-Pal-D-Trp-Lys-Val -Phe-Thr-NH 2 ;
  • H (CH 3 CO) -/3-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
  • H (4- (2-hydroxyethyl) -1-piperazinylacetyl) -j ⁇ -Nal-D- - Cpa-Pal -D-Trp-Lys-Val-Phe-Thr-NH 2 ;
  • H 2 -j ⁇ -Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
  • H (CH 3 CO) -/3-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
  • H (4- (2-hydroxyethyl) -1-piperazinylacetyl) -/3-Nal-D-- Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
  • N-terminal amino acid all abbreviations (e.g., Ala or A 2 ) of amino acids in this disclosure stand for the structure of -NH-CH (R) -CO- , wherein R is a side chain of an amino acid (e.g., CH 3 for Ala) .
  • R is a side chain of an amino acid.
  • Tyr (I) refers to an iodinated tyrosine residue (e.g., 3-1-Tyr, 5-I-Tyr, 3,5-I-Tyr) wherein the iodine may be a radioactive isotope, e.g., I 125 , I 127 , or I 131 .
  • An aliphic amino acid is an ⁇ -amino acid having one or two side chains which, independently, are hydrocarbons, e.g., a straight or branched chain of 1-6 carbons. Examples of aliphatic amino acids include Ala, Aib, Val, Leu, Tie, lie, Nle, Nva, or Abu.
  • An aromatic amino acid is an ⁇ -amino acid the side chain of which has a neutral (e.g., not acidic or basic) aromatic substituent, e.g., a substituted or unsubstituted phenyl, naphthyl, or aromatic heterocycle group (e.g., pyridyl or indolyl) .
  • a neutral (e.g., not acidic or basic) aromatic substituent e.g., a substituted or unsubstituted phenyl, naphthyl, or aromatic heterocycle group (e.g., pyridyl or indolyl) .
  • aromatic amino acids examples include Phe, p-X-Phe (where X is a halo (e.g., F, Cl , Br, or I), OH, OCH 3 , CH 3 , or N0 2 ) , o-X-Phe (where X is a halo, OH, OCH 3 , CH 3 , or N0 2 ) , m-X-Phe (where X is a halo, OH, OCH 3 , CH 3 , or N0 2 ) , His, Pal, Trp, j ⁇ -Nal, 2, 4-dichloro-Phe, Tyr (I), ⁇ - [3,4,5- trifluorophenyl] -alanine, Bta, ⁇ - [3 -cyanophenyl] alanine, ⁇ - [4-cyanophenyl] -alanine, ⁇ - [3 , 4 -difluorophenyl] -alanine, ⁇ -
  • an “Eaa” is an amino acid of the formula -NH- [CH(R) n ,-CO- (where n is 2-6 and R is H, lower alkyl, or hydroxy lower alkyl) .
  • Examples of an Eaa include j ⁇ -Ala and Gaba.
  • "lower alkyl” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having 1-6 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl , isopropyl, butyl, t-butyl, isobutyl, sec-butyl, and the like.
  • aryl is intended to include any stable monocyclic, bicyclic, or tricyclic carbon ring(s) of up to 7 members in each ring, wherein at least one ring is aromatic.
  • aryl groups include phenyl, naphthyl, anthracenyl , biphenyl , tetrahydronaphthyl , indanyl , phenanthrenyl , and the like.
  • heterocyclyl represents a stable 5- to 7-membered monocyclic or stable 8- to 11- membered bicyclic or stable 11-15 membered tricyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure.
  • heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl , benzisoxazolyl , benzofurazanyl , benzopyranyl , benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl , cinnolinyl, dihydrobenzofuryl , dihydrobenzothienyl , dihydrobenzothiopyranyl , dihydrobenzothio-pyranyl sulfone, furyl , imidazolidinyl , imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl , isoindolinyl , isoquinol inyl , isothiazolidinyl , i sothia zolyl , i sothiazol idiny1 ,
  • substituted is meant to include the recited chemical group (e.g., lower alkyl, heterocycle, aryl, cycloalkyl, etc.) substituted with one to four of the recited substituents (e.g., halo, hydroxy, lower alkyl, etc.) .
  • the substituent may be attached to any atom in the chemical group.
  • the compounds of this invention can be provided in the form of pharmaceutically acceptable salts.
  • Acceptable salts include, but are not limited to, acid addition salts of inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide , and nitrate or organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p- toluenesulfonate, pamoate, salicylate, oxalate, and stearate .
  • salts formed from bases such as sodium or- potassium hydroxide.
  • bases such as sodium or- potassium hydroxide.
  • amino acid residue is optically active, it is the L-isomer that is intended unless otherwise specified.
  • the disulfide bond between the thiol group on the side chain of residue A 2 (e.g., Cys, Pen, D-Cys, or D-Pen) and the thiol group on the side chain of residue A 7 (e.g., Cys or Pen) is not shown.
  • the peptides of the invention can be used to promote the release of growth hormone or insulin in a subject
  • the peptides are useful in the treatment of physiological conditions in which the promotion of the release of growth hormone or insulin is of benefit.
  • the peptides of the invention can also be used in enhancing wound healing or promoting angiogenesis .
  • peptides of the invention having a Tyr(l) residue can be used to image cells containing somatostatin receptors.
  • Such peptides of the invention can be used either in vivo to detect cells having somatostatin receptors (e.g., cancer cells) or in vi tro as a radioligand in a somatostatin receptor binding assay.
  • the peptide of the invention can also be used as vectors to target cells with radioactive isotopes.
  • a therapeutically effective amount of a peptide of this invention and a pharmaceutically acceptable carrier substance e.g., magnesium carbonate, lactose, or a phospholipid with which the therapeutic compound can form a micelle
  • a pharmaceutically acceptable carrier substance e.g., magnesium carbonate, lactose, or a phospholipid with which the therapeutic compound can form a micelle
  • a therapeutic composition e.g., a pill, tablet, capsule, or liquid
  • the pill, tablet, or capsule can be coated with a substance capable of protecting the composition from the gastric acid or intestinal enzymes in the subject's stomach for a period of time sufficient to allow the composition to pass undigested into the subject's small intestine.
  • the therapeutic composition can' also be in the form of a biodegradable or nonbiodegradable sustained release formulation for subcutaneous or intramuscular administration. See, e.g., U.S. Patents 3,773,919 and 4,767,628 and PCT Application No. WO 94/00148. Continuous administration can also be obtained using an implantable or external pump (e.g., INFUSAID TM pump) to administer the therapeutic composition.
  • a peptide of the present invention for treating the above-mentioned diseases or disorders varies depending upon the manner of administration, the age and the body weight of the subject, and the condition of the subject to be treated, and ultimately will be decided by the attending physician or veterinarian.
  • Such an amount of the peptide as determined by the attending physician or veterinarian is referred to herein as a "therapeutically effective amount”.
  • peptide covered by the above generic formula for both use in treating diseases or disorders associated with the need to promote the release of growth hormone or insulin, and use in detecting somatostatin receptors, e.g., radioimaging .
  • Other peptides of the invention can be prepared in an analogous manner by a person of ordinary skill in the art .
  • Benzhhydrylamine-polystyrene resin (Advanced ChemTech, Inc., Louisville, KY) (1.2 g; 0.5 mmole) in the chloride ion form was placed in the reaction vessel of an Advanced ChemTechTM peptide synthesizer programmed to perform the following reaction cycle: (a) methylene chloride; (b) 33% trifluoroacetic acid in methylene chloride (2 times for 1 and 25 min each); (c) methylene chloride; (d) ethanol; (e) methylene chloride; and (f) 10% triethylamine in chloroform.
  • the neutralized resin was stirred with Boc-0-/3- naphthylalanine and diisopropylcarbodiimide (1.5 mmole each) in methylene chloride for 1 hr, and the resulting amino acid resin was then cycled through steps (a) to (f) in the above wash program.
  • the following amino acids (1.5 mmole) were then coupled successively by the same procedure: Boc-S-methylbenzyl-Cys , Boc-Val, Boc-N e - benzyloxycarbonyl-lysine, Boc-D-Trp, Boc-Pal, and Boc-S- methylbenzyl -D-Cys and Boc-/3-Nal.
  • Boc-S-methylbenzyl -D-Cys Boc-/3-Nal.
  • Benzhydrylamine-polystyrene resin (Advanced ChemTechTM, Inc.) (1.2 g, 0.5 mmole) in the chloride ion form was placed in the reaction vessel of an Advanced ChemTech peptide synthesizer programmed to perform the following reaction cycle: (a) methylene chloride; (b) 33% trifluoroacetic acid in methylene chloride (2 times for 1 and 25 min each); (c) methylene chloride; (d) ethanol; (e) methylene chloride; and (f) 10% triethylamine in chloroform.
  • the neutralized resin was stirred with Boc-0- benzylthreonine and diisopropylcarbodiimide (1.5 mmole each) in methylene chloride for 1 hr and the resulting amino acid resin was cycled through steps (a) to (f) in the above wash program.
  • the following amino acids (1.5 mmole) were then coupled successively by the same procedure: Boc- phenylalanine, Boc-Val, Boc-N e -benzyloxycarbonyl-lysine, Boc-D-Trp, Boc- 0-dichlorobenzyl -Tyr, and Boc-D-4- chlorophenylalanine, and Boc-/3-D-Nal .
  • Boc-phenylalanine Boc-Val
  • Boc-N e -benzyloxycarbonyl-lysine Boc-D-Trp
  • Boc-D-4- chlorophenylalanine Boc-/3-D-Nal .
  • Peptides containing C-terminal substituted amides can be made by solid phase methods by displacing the appropriate peptide off the solid phase with the corresponding amine .
  • these analogs may be synthesized by solutionphase peptide synthesis methods in which the growing peptide chain is maintained in solution in an organic solvent during synthesis and assembled by iterative coupling/deprotection cycles. Final removal of the side chain protecting groups yields the desired peptide after appropriate purification.
  • Peptides containing N- terminal substitutions e.g., where R x is E, CO, or E- L S0 2
  • E x is heterocycle lower alkyl substituted with hydroxy lower alkyl and R 2 is H such as 4- (2- hydroxyethyl) -
  • the vial contents then were poured into a scintillation vial containing 2 ml 0.1% DNase (Sigma Chemical Co., St. Louis, MO) in KRBGA and incubated for 2 min at 37°C with agitation. After incubation, the tissue was decanted into a 15 ml centrifuge tube and allowed to settle. Medium was discarded, and pituitary sections were washed 3 times with 1 ml fresh KRBGA. The cells were then dispersed in 2 ml 0.05% LBI (lima bean trypsin inhibitor, Worthington Biochemicals) by gently drawing the fragments into and expelling them out of a siliconized, fire polished Pasteur pipette.
  • LBI lima bean trypsin inhibitor
  • the dispersed cells were then further diluted with approximately 15 ml sterile- filtered Dulbeccol ' s modified Eagle medium (GIBCO) , which was supplemented with 2.5% fetal calf serum (GIBCO) , 3% horse serum (GIBCO) , 10% fresh rat serum (stored on ice for no longer than 1 hr) from the pituitary donors, 1% MEM non-essential amino acids (GIBCO) , and gentamycin (10 ng/ml; Sigma) and nystatin (10,000 U/ml ; GIBCO) .
  • GEBCO sterile- filtered Dulbeccol ' s modified Eagle medium
  • the cells were poured into a 50 ml round-bottomed glass extraction flask with a large diameter opening and then randomly plated at a density of approximately 200,000 cells per well (Co-star cluster 24; Rochester Scientific Co., Rochester, NY) .
  • the plated cells were maintained in the above Dulbeccols medium in a humidified atmosphere of 95% air and 5% C0 2 at 37°C for 4-5 days.
  • each treatment well contained a total volume of 1 ml medium 199 containing 1% BSA (fraction V; Sigma) with treatments as described below.
  • Each antagonist candidate was tested using a single 24 -well cell culture plate. Each treatment was performed in triplicate.
  • Each plate contained 8 treatment groups : one 1 nM growth hormone releasing factor (GRF) (1-29) NH 2 -stimulated control group; one 1 nM somatostatin- inhibited control group in the presence of 1 nM GRF (1-29) NH 2 ; and 6 doses of a given antagonist in the presence of both 1 nM SRIF and 1 nM GRF per plate.
  • GRF growth hormone releasing factor
  • IC 50 's of each antagonist versus 1 nm @ SRIF were calculated using a computer program ( SigmaPlot, Jandel Scientific, San Rafael, CA) with the maximum response constrained to the value of the 1 nm GRF (1-29) NH 2 -stimulated control. These IC 50 's are presented in Table I.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des antagonistes de la somatostatine, possédant un acide aminé D au niveau du second reste.
PCT/US1997/022251 1996-12-04 1997-12-04 Antagonistes de la somatostatine Ceased WO1998024807A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PL97334089A PL334089A1 (en) 1996-12-04 1997-12-04 Compounds antagonistic in respect to somatostatin
CA002274144A CA2274144C (fr) 1996-12-04 1997-12-04 Antagonistes de la somatostatine
DE69736193T DE69736193T2 (de) 1996-12-04 1997-12-04 Somatostatin-antagonisten
KR10-1999-7004835A KR100479149B1 (ko) 1996-12-04 1997-12-04 소마토스타틴 길항제
BR9714376A BR9714376A (pt) 1996-12-04 1997-12-04 Antagonistas de somatostatina
NZ335879A NZ335879A (en) 1996-12-04 1997-12-04 Somatostatin antagonist peptides having a D-amino acid at the second residue
IL13016697A IL130166A0 (en) 1996-12-04 1997-12-04 Somatostatin antagonists
AU76248/98A AU728224B2 (en) 1996-12-04 1997-12-04 Somatostatin antagonists
JP52580198A JP4124820B2 (ja) 1996-12-04 1997-12-04 ソマトスタチン類似体
MXPA99004944A MXPA99004944A (es) 1996-12-04 1997-12-04 Antagonistas de somatostatina.
EP97949758A EP0956296B1 (fr) 1996-12-04 1997-12-04 Antagonistes de la somatostatine

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US3235896P 1996-12-04 1996-12-04
US76067296A 1996-12-04 1996-12-04
US60/032,358 1996-12-04
US08/855,204 US6262229B1 (en) 1996-12-04 1997-05-13 Somatostatin antagonists
US08/760,672 1997-05-13
US08/855,204 1997-05-13

Publications (2)

Publication Number Publication Date
WO1998024807A2 true WO1998024807A2 (fr) 1998-06-11
WO1998024807A3 WO1998024807A3 (fr) 1998-10-15

Family

ID=27364103

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/022251 Ceased WO1998024807A2 (fr) 1996-12-04 1997-12-04 Antagonistes de la somatostatine

Country Status (17)

Country Link
EP (1) EP0956296B1 (fr)
JP (2) JP4124820B2 (fr)
KR (1) KR100479149B1 (fr)
AT (1) ATE330966T1 (fr)
AU (1) AU728224B2 (fr)
BR (1) BR9714376A (fr)
CA (1) CA2274144C (fr)
DE (1) DE69736193T2 (fr)
ES (1) ES2264174T3 (fr)
HU (1) HUP0003396A3 (fr)
IL (1) IL130166A0 (fr)
MX (1) MXPA99004944A (fr)
NZ (1) NZ335879A (fr)
PL (1) PL334089A1 (fr)
RU (1) RU2179172C2 (fr)
TW (1) TW575582B (fr)
WO (1) WO1998024807A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000676A1 (fr) * 1999-06-25 2001-01-04 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Agonistes de la somatostatine
WO2002072602A3 (fr) * 2001-03-08 2003-03-20 Univ Tulane Antagonistes de la somatostatine
JP2004531520A (ja) * 2001-04-09 2004-10-14 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド ソマトスタチンアゴニスト
US6864234B1 (en) 1999-06-25 2005-03-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Somatostatin agonists
RU2263680C2 (ru) * 1999-06-04 2005-11-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас Агонисты рецепторов нейромедина в и соматостатина
WO2008048942A2 (fr) 2006-10-16 2008-04-24 The Salk Institute For Biological Studies Antagonistes de la somatostatine sélectifs du récepteur sstr2
WO2011151782A1 (fr) 2010-06-02 2011-12-08 Preglem Sa Rôle de la somatostatine pour moduler l'initiation de la croissance folliculaire dans l'ovaire humain
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2521965A1 (fr) * 2003-04-11 2004-10-28 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Analogues chimeres de la somatostatine-dopamine
ES2351569B8 (es) * 2009-05-07 2012-06-20 Bcn Peptides S.A. Ligandos peptídicos de receptores de somatostatina.
EP2399931A1 (fr) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Nouveaux composés octapeptidiques et leur utilisation thérapeutique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3917581A (en) * 1974-08-01 1975-11-04 Ayerst Mckenna & Harrison Derivatives of somatostatin and process therefor
HUT42101A (en) * 1985-01-07 1987-06-29 Sandoz Ag Process for preparing stomatostatine derivatives and pharmaceutical compositions containing such compounds
US4904642A (en) * 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US5073541A (en) * 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
US5633263A (en) * 1989-04-26 1997-05-27 The Administrators Of The Tulane Educational Fund Linear somatostatin analogs
WO1990012811A1 (fr) * 1989-04-26 1990-11-01 The Administrators Of The Tulane Educational Fund Analogues lineaires de somatostatine
US5708135A (en) * 1995-09-29 1998-01-13 Biomeasure Incorporated Cyclic peptide analogs of somatostatin

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2263680C2 (ru) * 1999-06-04 2005-11-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик Сас Агонисты рецепторов нейромедина в и соматостатина
RU2263677C2 (ru) * 1999-06-25 2005-11-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С. Агонисты соматостатина
WO2001000676A1 (fr) * 1999-06-25 2001-01-04 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Agonistes de la somatostatine
US7144859B2 (en) 1999-06-25 2006-12-05 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Somatostatin agonists
US6864234B1 (en) 1999-06-25 2005-03-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Somatostatin agonists
RU2328504C2 (ru) * 2001-03-08 2008-07-10 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Антагонисты соматостатина
US7408024B2 (en) 2001-03-08 2008-08-05 The Administrators Of The Tulane Educational Fund Somatostatin antagonists
RU2263678C2 (ru) * 2001-03-08 2005-11-10 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Антагонисты соматостатина
US7378488B2 (en) 2001-03-08 2008-05-27 The Administrators Of The Tulane Educational Fund Somatostatin antagonists
WO2002072602A3 (fr) * 2001-03-08 2003-03-20 Univ Tulane Antagonistes de la somatostatine
JP2004531520A (ja) * 2001-04-09 2004-10-14 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド ソマトスタチンアゴニスト
US7960342B2 (en) 2006-10-16 2011-06-14 The Salk Institute For Biological Studies Receptor(SSTR2)-selective somatostatin antagonists
WO2008048942A3 (fr) * 2006-10-16 2008-09-18 Salk Inst For Biological Studi Antagonistes de la somatostatine sélectifs du récepteur sstr2
JP2010506943A (ja) * 2006-10-16 2010-03-04 ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ 受容体（ｓｓｔｒ２）選択的ソマトスタチンアンタゴニスト
WO2008048942A2 (fr) 2006-10-16 2008-04-24 The Salk Institute For Biological Studies Antagonistes de la somatostatine sélectifs du récepteur sstr2
EP2383289A1 (fr) * 2006-10-16 2011-11-02 The Salk Institute for Biological Studies Antagonistes de la somatostatine sélectifs du récepteur SSTR2
EP2433963A1 (fr) * 2006-10-16 2012-03-28 The Salk Institute for Biological Studies Antagonistes de la somatostatine sélectifs du récepteur SSTR2
CN101631801B (zh) * 2006-10-16 2013-06-05 索尔克生物学研究院 受体（sstr2）-选择性生长抑素拮抗剂
AU2007311137B2 (en) * 2006-10-16 2013-06-20 The Salk Institute For Biological Studies Receptor(SSTR2)-selective somatostatin antagonists
US8501687B2 (en) 2006-10-16 2013-08-06 Jean E. F. Rivier Receptor(SSTR2)-selective somatostatin antagonists
CN103288919A (zh) * 2006-10-16 2013-09-11 索尔克生物学研究院 受体(sstr2)-选择性生长抑素拮抗剂
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
WO2011151782A1 (fr) 2010-06-02 2011-12-08 Preglem Sa Rôle de la somatostatine pour moduler l'initiation de la croissance folliculaire dans l'ovaire humain

Also Published As

Publication number Publication date
JP4124820B2 (ja) 2008-07-23
KR100479149B1 (ko) 2005-03-25
EP0956296B1 (fr) 2006-06-21
EP0956296A2 (fr) 1999-11-17
AU728224B2 (en) 2001-01-04
AU7624898A (en) 1998-06-29
RU2179172C2 (ru) 2002-02-10
PL334089A1 (en) 2000-01-31
DE69736193T2 (de) 2007-05-03
HUP0003396A3 (en) 2001-03-28
MXPA99004944A (es) 2004-09-10
CA2274144C (fr) 2004-03-30
CA2274144A1 (fr) 1998-06-11
NZ335879A (en) 2000-11-24
ATE330966T1 (de) 2006-07-15
HUP0003396A1 (hu) 2001-02-28
DE69736193D1 (de) 2006-08-03
ES2264174T3 (es) 2006-12-16
JP2001505580A (ja) 2001-04-24
JP2008120818A (ja) 2008-05-29
BR9714376A (pt) 2000-03-21
WO1998024807A3 (fr) 1998-10-15
IL130166A0 (en) 2000-06-01
JP4264762B2 (ja) 2009-05-20
KR20000069243A (ko) 2000-11-25
TW575582B (en) 2004-02-11

Similar Documents

Publication Publication Date Title
US9133262B2 (en) Somatostatin antagonists
JP4264762B2 (ja) ソマトスタチン類似体
Veber et al. Conformationally restricted bicyclic analogs of somatostatin.
US5084555A (en) An octapeptide bombesin analog
EP0395417B1 (fr) Analogues linéaires de somatostatine
US5877277A (en) Octapeptide bombesin analogs
CA2229544C (fr) Analogues peptides cycliques de somatostatine
JPS60109600A (ja) 環状ヘキサペプチド，ソマトスタチン類似体
US4190648A (en) Peptides having somatostatin activity
PT99667B (pt) Processo de preparacao de nonapeptidos antagonistas da bombesina e de composicoes farmaceuticas que os contem
KR100629013B1 (ko) Ｉｇｆ-ⅰ 및 -ⅱ를 억제하는 ｇｈ-ｒｈ의 길항 유사체
EP2161037A2 (fr) Conjugués de Camptothecin-Somatostatin
EP0215171A2 (fr) Peptides
IE50364B1 (en) Cyclic hexapeptide somatostatin analogs,process for their preparation and pharmaceutical compositions containing them
RU2457218C2 (ru) Конъюгаты цитотоксических средств с пептидами
US5633263A (en) Linear somatostatin analogs
EP0214872A2 (fr) Analogues de somatostatine
JPS6241240B2 (fr)
CZ196399A3 (cs) Antagonisté somatostatinu
Moroder et al. Gastrin and Cholecystokinin: An Arduous Task for the Peptide Chemist
IE47454B1 (en) Somatostatin analogs
AU1136000A (en) Cyclic peptide analogs of somatostatin
HK1142011A (en) Camptothecin-somatostatin conjugates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page

Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 76248/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 335879

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/004944

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2274144

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2274144

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1997949758

Country of ref document: EP

Ref document number: 1019997004835

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV1999-1963

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 1998 525801

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997949758

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-1963

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997004835

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 76248/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1019997004835

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997949758

Country of ref document: EP